藥碼
OXA01
藥名
Oxaliplatin 5 mg/mL, 10 mL/Vial
英文商品名
化療 Oxalip 針 50 mg/10 mL/Vial
中文商品名
歐力普注射劑
螢幕名
化療 Oxalip 針 50 mg/10 mL/Vial
劑型
Inj
規格
成分
藥理分類
Antineoplastic Drugs
健保碼
AA44508229
ATC碼
適應症
1.Adjuvant treatment of Stage III colon cancer after complete resection of the primary tumor. 2.Treatment of advanced colorectal cancer. 3.Usually used in combination with fluorouracil (5-FU) and leucovorin.
藥理
Antineoplastic Drugs
藥動學
1.Administration: Intravenous infusion. 2.Distribution: Platinum rapidly binds to plasma proteins and erythrocytes. 3.Metabolism: Non-enzymatic biotransformation to active platinum complexes. 4.Elimination: Mainly via renal excretion. 5.Half-life: Multi-phase elimination with a prolonged terminal phase due to tissue binding.
禁忌症
History of hypersensitivity reactions to oxaliplatin or other platinum-based drugs (e.g., cisplatin, carboplatin).
懷孕分類
1.Not assigned under the newer FDA labeling system. 2.Risk summary: May cause fetal harm based on its DNA-damaging mechanism and animal studies.
哺乳分類
Breastfeeding is not recommended during treatment and for 3 months after the last dose, due to potential serious adverse reactions in breastfed infants.
副作用
Most common adverse reactions (?40% incidence): 1.Peripheral sensory neuropathy 2.Neutropenia 3.Thrombocytopenia 4.Anemia 5.Nausea and vomiting 6.Diarrhea 7.Fatigue 8.Stomatitis 9.Elevated liver enzymes (AST/ALT, ALP) 10.Oxaliplatin Serious adverse effects include: 1.Anaphylaxis / hypersensitivity reactions 2.Myelosuppression 3.Pulmonary toxicity 4.Posterior reversible encephalopathy syndrome (PRES) 5.QT interval prolongation 6.Rhabdomyolysis
劑量和給藥方法
Standard regimen (FOLFOX regimen): 1.Oxaliplatin: 85 mg/m2 IV infusion over 120 minutes, every 2 weeks 2.Given concurrently with leucovorin, followed by fluorouracil (5-FU). Treatment duration: 1.Adjuvant therapy: up to 12 cycles 2.Advanced colorectal cancer: until disease progression or unacceptable toxicity.
小兒調整劑量
Safety and efficacy in pediatric patients have not been established. Clinical trials in children showed sensory neuropathy as the dose-limiting toxicity.
腎功能調整劑量
Severe renal impairment (CrCl <30 mL/min):Reduce dose to 65 mg/m2.
肝功能調整劑量
1.No specific dose adjustment recommended. 2.Monitor liver function tests regularly due to risk of hepatotoxicity.
安定性
1.Dilute with 5% dextrose solution only (not saline). 2.Diluted solution stability: (1)6 hours at room temperature (20–25°C) (2)24 hours refrigerated (2–8°C) (3)Protect concentrate from light and do not freeze.
注射給藥指引
給藥途徑
靜脈輸注，可經由中央靜脈導管或週邊靜脈給藥。
Intravenous infusion, administered via a central venous catheter or peripheral vein.
靜脈輸注液
僅限使用 5% 葡萄糖注射液 (D5W) 進行稀釋。絕對不可使用生理食鹽水或任何含氯溶液調製。
Dilute only with 5% Glucose Injection (D5W). Never use Normal Saline or any chloride-containing solutions f
每瓶稀釋液體積
通常將藥液稀釋於 250 至 500 毫升之 5% 葡萄糖注射液中。
Usually diluted in 250 to 500 mL of 5% Glucose Injection.
注射濃度
給藥速率
建議給藥速率為持續靜脈點滴 2 至 6 小時。
The recommended administration rate is continuous intravenous infusion over 2 to 6 hours.
安定性
1.Dilute with 5% dextrose solution only (not saline). 2.Diluted solution stability: (1)6 hours at room temperature (20–25°C) (2)24 hours refrigerated (2–8°C) (3)Protect concentrate from light and do not freeze.
注意事項
藥袋資訊
臨床用途
化學治療藥
主要副作用
腸胃不適、骨髓抑制、肝功能異常、頭痛、神經痛、咳嗽、疲倦、發燒、掉髮、黏膜炎
泡製方法
儲存方式
請置於 15-30℃ 乾燥處儲存
注意事項
其他說明
化療藥局 化5 | 藥庫 化療
藥品外觀
顏色
形狀
剝痕
標記1
標記2
其他
健保藥價
679
自費價
903.07
仿單
資料庫
健保給付規定